Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
July 10, 2012Pharmacogenetics and Genomics

The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients

View Full Paper
Ask AI
Bookmark
Share

Authors

STSalvatore TerrazzinoMQMarco QuagliaPSPiero Stratta

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Terrazzino et al. (2012) studied this question.

synapsesocial.com/papers/6aa3bf8a037baa32b3555915https://doi.org/10.1097/fpc.0b013e3283557c74
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers2011 · 76 citations
  2. 2Evidence of Different Pharmacokinetics Including Relationship among <i>AUC</i>, Peak, and Trough Levels between Cyclosporine and Tacrolimus in Renal Transplant Recipients Using New Pharmacokinetic Parameter—Why Cyclosporine Is Monitored by <i>C</i><sub>2</sub> Level and Tacrolimus by Trough Level—2008 · 16 citations
  3. 3Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients2004 · 182 citations
  4. 4Donor Age and Renal P-Glycoprotein Expression Associate with Chronic Histological Damage in Renal Allografts2009 · 144 citations